SEARCH

SEARCH BY CITATION

Figure S1 Disease-specific survival (DSS) of the 61 patients as classified by the (a) World Health Organization (WHO), (b) European Neuroendocrine Tumor Society (ENETS), (c) Memorial Sloan-Kettering Cancer Center (MSKCC), (d) American Joint Committee for Cancer (AJCC) TNM and (e) Bilimoria classifications systems. B, benign; G, grade; M, malignant (well differentiated); mets, metastases; PD, poorly differentiated; U, uncertain.

Figure S2 Recurrence-free survival (RFS) of the 53 patients as classified by the (a) World Health Organization (WHO), (b) European Neuroendocrine Tumor Society (ENETS), (c) Memorial Sloan-Kettering Cancer Centre, (d) American Joint Committee for Cancer (AJCC) TNM and (e) Bilimoria classification systems. B, benign; G, grade; M, malignant (well-differentiated); mets, metastases; PD, poorly differentiated; U, uncertain.

FilenameFormatSizeDescription
ANS_5403_sm_f1.doc110KSupporting info item
ANS_5403_sm_f2.doc109KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.